Sundu Brahmasandra

Sundu Brahmasandra

Corporate Officer/Principal at LUMINEX CORPORATION
Health Technology
Consumer Services
Finance

Profile

Sundu Brahmasandra is an accomplished serial entrepreneur and brings more than 20 years of impressive leadership in all aspects of novel IVD product development, strategic planning, and operational management.
Most recently Sundu was the COO of Strata Oncology.
Prior to Strata, Sundu was the President & COO of NeuMoDx Molecular where he led the development of a multitude of molecular diagnostics assays on the revolutionary NeuMoDx 288 and NeuMoDx 96 Molecular Systems.
NeuMoDx was acquired by QIAGEN in 2020.
Prior to NeuMoDx Sundu co-founded HandyLab, Inc and led the development of the HandyLab Jaguar (aka BD MAX) System.
HandyLab was acquired by BD in 2009.
Sundu holds a B.Tech in Chemical Engineering from IIT-Madras and a PhD in Chemical Engineering from the University of Michigan, Ann Arbor.

Sundu Brahmasandra active positions

CompaniesPositionStart
LUMINEX CORPORATION Corporate Officer/Principal 01/02/2023
Consultant / Advisor 01/01/2014
Director/Board Member 01/01/2022
Consultant / Advisor 01/01/2019

Former positions of Sundu Brahmasandra

CompaniesPositionEnd
Chief Operating Officer 01/09/2022
QIAGEN N.V. Corporate Officer/Principal 31/03/2021
President 01/09/2020
President 01/06/2012
BECTON, DICKINSON AND COMPANY Private Equity Investor 01/03/2011
See the detail of Sundu Brahmasandra's experience

Training of Sundu Brahmasandra

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

85

1st degree connections

13

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies13

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Finance

  1. Stock Market
  2. Insiders
  3. Sundu Brahmasandra